BioStem Technologies, Inc. (OTC Pink: BSEM) Acquires Their First FDA Approved Branded Generic Drug (ANDA) -- Granisol® Oral Solution

August 22, 2016

OAKLAND PARK, FL--(Marketwired - Aug 22, 2016) -  BioStem Technologies, Inc. (OTC PINK: BSEM) (the "Company" or "BioStem"), announced today that it has acquired its first FDA approved branded generic drug (ANDA), Granisol® Oral Solution ("Granisol"), an effective medicine for preventing nausea and vomiting associated with cancer chemotherapy and radiation treatments.


Henry Van Vurst, CEO of BioStem Technologies, commented, "As a surviving cancer patient myself, I know first-hand the uncomfortable feelings of nausea while undergoing chemotherapy. We are very excited to announce our acquisition of Granisol -- a drug that relieves a major pain point for patients during this time. We look forward to marketing it effectively and profitably, and helping cancer patients feel better while fighting a very difficult battle." 


Granisol® Oral Solution is proven to be a highly effective anti-nauseant during initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin, total body irradiation, and fractionated abdominal radiation. Granisol® contains granisetron hydrochloride, an antiemetic (anti-nauseant) agent. The recommended adult dosage is 2 mg once daily, or 1 mg twice daily. In the 2 mg once-daily regimen, 10 mL of Granisol Oral Solution (2 teaspoonsful, equivalent to 2 mg of granisetron) are given up to 1 hour before chemotherapy. In the 1 mg twice-daily regimen, the first teaspoonful (5 mL) of Granisol Oral Solution is given up to 1 hour before chemotherapy, and the second teaspoonful (5 mL) of Granisol Oral Solution, 12 hours after the first. Either regimen is administered only on the day(s) chemotherapy is given.


About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies (OTC PINK: BSEM) is in the business of regenerative medicine and antiaging strategies throughout the United States, Europe, and Mexico. The Company's mission is to conquer the effects of biological aging (and related acute disease), and its strategy is to discover, develop, produce, and deliver the most effective stem cell and wellness products in the world. The Company is comprised of a diverse group of scientists, physicians, and industry visionaries who are creating innovative products for helping customers live their best, feel their best, and be their best. The company operates four strategic business units -- BioStem Cell Therapy, BioStem Wellness, BioStem Pharmaceuticals, and BioStem International -- providing a diversified line of products and services that include: clinical stem cell therapy, stem cell R&D, state-of-the-art laboratory services, pharmaceuticals, nutraceuticals, cosmeceuticals, API Repackaging, and medical tourism.


Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.


Share on Facebook
Share on Twitter
Please reload

Featured Posts

BioStem Technologies Releases Third Quarter 2018 Shareholder Update

December 10, 2018

Please reload

Recent Posts
Please reload